|INBRX-109 in conventional chondrosarcoma
This study is a randomized, blinded, placebo-controlled phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.
Further information can be found on clinicaltrials.gov.
WHO is the trial for?
WHAT is the key question that this trial is attempting to answer?
|The study evaluates the efficacy, tolerability and quality of life of patients receiving INBRX-109 who have metastatic or unresectable conventional chondrosarcoma.
WHY patients might want to participate?
|This clinical trial offers patients an opportunity to access a new therapy strategy. This trial will further support the research in sarcoma and potentially help other patients with this disease.
The trial might or might not have benefit in your individual case.
WHEN will the trial be open?
|The study is open for recruitment.
WHERE is the trial available?
|The trial is currently active in the US, France, Germany, Ireland, Italy, Netherlands, Spain and the UK.
Please check for current information here.
Kevin Bayer, firstname.lastname@example.org
STUDY DESIGN: What does the study look like?
|There are 2 study arms (groups): all participating patients will be randomly divided (by a computer) in two groups. Patients in one group will be assigned to INBRX-109, the other group will receive placebo.
Both will be given as IV therapy every three weeks.
Patients on placebo are allowed to cross-over to the INBRX-109 arm in case their disease progresses.
HOW do I get more information?
|Patient organizations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organizations serving sarcoma patients. If there are no such organization in your country, please email us for more information: email@example.com
Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.